Our experience
Our work in gene therapy spans the full spectrum of innovation – from early-stage discovery to clinical translation and commercial rollout. We collaborate with pioneering biotech firms, academic institutions, and spin-out ventures that are reshaping the future of medicine through these technologies.
Our developers have supported developers of viral and non-viral delivery platforms for gene editing and expression, innovators working on mRNA-based therapies, CRISPR systems, and synthetic biology, research teams advancing treatments for rare diseases, oncology, and regenerative medicine, and diagnostic companies leveraging gene expression profiling and biomarker discovery.
We are frequently engaged in patent strategy development for platform technologies, therapeutic pipelines, and companion diagnostics. Our experience includes navigating complex regulatory landscapes, advising on patent term extensions, and managing global portfolios with precision.
Our expertise
Our Cell & gene therapy group includes attorneys with academic backgrounds in biochemistry, molecular biology, immunology, and genetics.
We offer deep technical and legal expertise across a wide range of gene therapy technologies, including gene delivery vectors, gene and protein engineering, RNA therapeutics and mRNA-based vaccines, and reporter T-cells and chimeric vaccines.
Our attorneys are highly experienced in drafting and prosecuting patent applications in these areas and regularly attend specialist cell and gene therapy conferences to stay abreast of the latest technologies, regulations, and industry developments.
We understand the challenges of patenting in this rapidly evolving field and work closely with clients to secure robust protection strategies that reflect both scientific innovation and commercial realities.
For further information please contact:
